Latest News
SGI-DNA Equipping Researchers with Tools to Combat Coronavirus Disease
24 February 2020 - - US-based synthetic biology company SGI-DNA, creators of the BioXp 3200 System and Gibson Assembly Reagents, has launched a focused effort to empower organisations to accelerate research focused on creating vaccines for SARS-...
US Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications for Keytruda Six-Week Dosing Schedule
24 February 2020 - - The US Food and Drug Administration has issued a Complete Response Letter regarding US-based pharmaceutical company Merck's (NYSE: MRK) supplemental Biologics License Applications (sBLAs) seeking to update the dosing frequen...
FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People with Advanced Non-small Cell Lung Cancer
24 February 2020 - - The US Food and Drug Administration has accepted US-based biotechnology company Genentech's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) as a first-line (initial) m...
Cellectis and Servier Expand Collaboration on UCART19 Products
24 February 2020 - - France-based biopharmaceutical company Cellectis (PAR: ALCLS) (NASDAQ: CLLS) (Euronext Growth: ALCLS) (NASDAQ: CLLS) and pharmaceutical company Servier have executed a binding term sheet to enter into an amendment to th...
Lundbeck reports US FDA approval of its Vyepti as intravenous preventive treatment for migraine
24 February 2020 - H. Lundbeck A/S (PH:LUN), a global pharmaceutical company specialised in brain diseases, announced on Saturday the approval of Vyepti (eptinezumab-jjmr) by the US Food and Drug Administration (FDA) for the preventive treatment of m...